|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||374.16 - 393.83|
|52 Week Range||340.10 - 466.14|
|Beta (5Y Monthly)||0.30|
|PE Ratio (TTM)||20.65|
|Forward Dividend & Yield||9.97 (2.41%)|
|Ex-Dividend Date||Mar 17, 2022|
|1y Target Est||N/A|
NVS vs. RHHBY: Which Stock Is the Better Value Option?
The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.
Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to placebo.